Advertisement

Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Phase I trial and pharmacokinetic study of intravenous and oral α-Difluoromethylornithine

Abstract

Eflornithine-HCl (α-difluoromethylornithine or DFMO), an irreversible inhibitor of ornithine decarboxylase, blocks polyamine synthesis and has demonstrated antitumor activity in cell culture and animal tumor models. This phase I study was designed to determine and compare toxicity and the maximally tolerated dose of a 4-day course of DFMO given to patients in oral, continuous intravenous infusion or pulse intravenous infusion forms. Twenty-four patients were entered into this study: 8 received intravenous pulse drug, 10 intravenous continuous infusion of drug, and 6 oral DFMO. The most frequent toxicity was nausea and vomiting which occurred in 9 courses of oral drug. Only two patients receiving intravenous DFMO had nausea and vomiting. Clinically significant thrombocytopenia and audiometric abnormalities were not encountered in contrast to previous experience with 28-day courses of oral DFMO. The maximally tolerated dose of a four-day course of oral DFMO was 3.75 gm/M2 every 6 hours. The maximally tolerated dose of intravenous pulse and continuous infusion DFMO was not attained. Pharmacokinetic studies demonstrated that the intravenous schedules achieved higher plasma levels of DFMO than those previously obtained with chronic oral dosing.

This is a preview of subscription content, log in to check access.

References

  1. 1.

    Sjoerdsma A, Schechter PJ: Chemotherapeutic implications of polyamine biosynthesis inhibition. Clin Pharmacol Ther 35:287–300, 1984

  2. 2.

    Metcalf R, Bey P, Danzin C, Jung MJ, Cassara P, Vevert JP: Catalytic irreversible inhibition of mammalian ornithine decarboxylase (E.C. 4.1.1.17) by substrate and product analogues. J Am Chem Soc 100:2551–2553, 1978

  3. 3.

    Pegg AE, McCann PP: Polyamine metabolism and function. Am J Physiol 243:C212-C221, 1982

  4. 4.

    Mamont PS, Dechesne MC, Grove J, Bey P: Antiproliferative properties of DL-α-difluoromethylornithine in cultured cells. A consequence of the irreversible inhibition of ornithine decarboxylase. Biochem Biophys Res Commun 81:58–66, 1978

  5. 5.

    Prakash NJ, Schechter PJ, Grove J, Koch-Weser J: Effect of alpha-difluoromethylornithine, an enzyme-activated irreversible inhibitor of ornithine decarboxylase on L1210 leukemia in mice. Cancer Res 38:3059–3062, 1978

  6. 6.

    Prakash NJ, Schechter PH, Mamont PS, Grove J, Koch-Weser J, Sjoerdsma A: Inhibition of EMT 6 tumor growth by interference with polyamine biosynthesis; effects of alpha-difluoromethylornithine, an irreversible inhibitor of ornithine decarboxylase. Life Sci 26:181–194, 1980

  7. 7.

    Bartholeyns J: Treatment of metastatic Lewis lung carcinoma with DL-α-difluoromethylornithine. Eur J Cancer Clin Oncol 19:567–572, 1987

  8. 8.

    Luk GD, Civin CI, Weissman RM, Baylin SB: Ornithine decarboxylase: essential in proliferation but not differentiation of human promyelocytic leukemia cells. Science 216:75–77, 1982

  9. 9.

    Luk GD, Goodwin G, Marton LJ, Baylin S: Polyamines are necessary for the survival of human small-cell carcinoma in culture. Proc Natl Acad Sci USA 78:2355–2358, 1981

  10. 10.

    Sunkara PS, Fowler SR, Nishioka K, Rao PN: Inhibition of polyamine biosynthesis by alpha-difluoromethylornithine potentiates the cytotoxic effects of arabinosyl cytosine in HeLa cells. Biochem Biophys Res Commun 95:423–430, 1980

  11. 11.

    Chang BK, Black Jr O, Gutman R: Inhibition of growth of human or hamster pancreatic cancer cell lines by α-difluoromethylornithine alone and combined with cis-diamminedichloroplatinum (11). Cancer Res 44:5100–5104, 1984

  12. 12.

    Hung DT, Deen DF, Seidenfeld J, Marton LJ: Sensitization of 9L rat brain gliosarcoma cells to 1,3,-bis (2-chloroethyl)-1-nitrosourea by α-difluoromethylornithine, an ornithine decarboxylase inhibitor. Cancer Res 41:2783–2785, 1981

  13. 13.

    Bartholeyns J, Koch-Weser J: Effects of α-difluoromethylornithine alone and combined with Adriamycin and vindesine on L1210 leukemia in mice, EMT 6 solid tumors in mice, and solid tumors induced by injection of hepatoma tissue culture cells in rats. Cancer Res 41:5158–5161, 1981

  14. 14.

    Talpaz M, Quesada J, Gutterman JU: Phase I study of difluoromethylornithine (DFMO) and leukocyte interferon (INF) in cancer patients (Abstract). Proc Am Soc Clin Oncol 3:246, 1984

  15. 15.

    Abeloff MD, Slavik M, Luk GD, Griffin CA, Hermann J, Blanc O, Sjoerdsma A, Baylin S: Phase I trial and pharmacokinetic studies of α-difluoromethylornithine — an inhibitor of polyamine biosynthesis. J Clin Oncol 2:124–130, 1984

  16. 16.

    Abeloff M, Rosen S, Luk G, Baylin S, Zeltzman M, Sjoerdsma A: Phase II trials of α-difluoromethylornithine (DFMO), an inhibitor of polyamine synthesis, in advanced small cell lung cancer (SCLC) and colon cancer (CC) (Abstract). Proc Am Soc Clin Oncol 4:705, 1985

  17. 17.

    Haegele KD, Alken RG, Grove J, Schechter PJ, Koch-Weser J: Kinetics of α-difluoromethylornithine: an irreversible inhibitor of ornithine decarboxylase. Clin Pharmacol Ther 30:210–217, 1981

  18. 18.

    Grove J, Fozard JR, Mamont PS: Assay of α-difluoromethylornithine in body fluids and tissues by automatic amino acid analysis. J Chromatogr 223: 409–416, 1981

  19. 19.

    Slavik M, Mayfield A, Wood A, Blanc O: Pharmacokinetic studies with α-difluoromethylornithine (αDFMO) (Abstract). Proc Am Assoc Cancer Res 23:203, 1982

  20. 20.

    Gibaldi M, Perrier D: Pharmacokinetics. New York, Marcel Dekker, 1975, pp. 281–292

  21. 21.

    Ritschell WA: Handbook of Basic Pharmacokinetics. Hamilton, Illinois, Drug Intelligence Publications, Inc., 1980, p. 293

  22. 22.

    Luk GD, Sharkis SJ, Abeloff MD, McCann PP, Sjoerdsma A, Baylin SB: Polyamine biosynthesis is required for the maintenance of peripheral blood elements in the rat. Proc Natl Acad Sci USA 80:5090–5093, 1983

  23. 23.

    Golden JA, Sjoerdsma A, Santi DV: Pneumocystis carinii pneumonia treated with α-difluoromethylornithine. West J Med 141:613–623, 1984

  24. 24.

    Luk GD, Abeloff MD, Griffin CA, Baylin SB: Successful treatment with DL-α-difluoromethylornithine in established human small cell variant lung carcinoma implants in athymic mice. Cancer Res 43:4239–4243, 1983

Download references

Author information

Correspondence to Martin D. Abeloff.

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Griffin, C.A., Slavik, M., Chien, S.C. et al. Phase I trial and pharmacokinetic study of intravenous and oral α-Difluoromethylornithine. Invest New Drugs 5, 177–186 (1987). https://doi.org/10.1007/BF00203544

Download citation

Key words

  • α-difluoromethylornithine
  • phase I study
  • pharmacokinetics
  • polyamines